Abstract. In order to investigate the mechanism by which oligodendrogliomas cause neuronal damage, media conditioned by G26/24 oligodendroglioma cells, were fractionated into shed vesicles and vesicle-free supernatants, and added to primary cultures of rat fetal cortical neurons. After one night treatment with vesicles, a reproducible, dose-dependent, inhibitory effect on neurite outgrowth was already induced and, after 48-72 h of incubation, neuronal apoptosis was evident. Vesicle-free supernatants and vesicles shed by NIH-3T3 cells had no inhibitory effects on neurons. Western blot analyses showed that treated neurons expressed a decreased amount of neurofilament (NF), growth-associated protein (GAP-43) and microtubule-associated protein (MAP-2). Moreover procaspase-3 and -8 were activated while Bcl-2 expression was reduced. Vesicles were found positive for the proapoptotic molecule, Fas-ligand (Fas-L), and for the B isoform of Nogo protein, a myelin component with inhibitory effects on neurons. Nogo B involvement in the vesicle effects was analyzed both by testing the neutralizing capability of anti-Nogo antibodies and by removing the Nogo receptor from neurons by phospholipase C digestion. These treatments did not revert the vesicle effects. To test the role of Fas-L, vesicles were treated with functional anti-Fas-L monoclonals. Vesicle inhibitory and proapoptotic effects were reduced. Vesicles shed by ovarian carcinoma cells (OvCa), which are known to vehicle biologically active Fas-L, had similar effects on neurons to those of oligodendroglioma vesicles, and their inhibitory effects were also reduced by anti Fas-L antibodies. We therefore conclude that vesicles shed by G26/24 cells induce neuronal apoptosis at least partially by a Fas-L mediated mechanism.
Introduction
Oligodendrogliomas are considered as benign brain tumors for their slow growth rate but are biologically 'malign' due to the difficulty of surgically resecting them and for their ability to invade normal nervous tissue. The expansive growth of these brain tumors causes a rise in intracranial pressure, neuronal damage, and seizure (such as chronic epilepsy), which are frequent causes of patient death (1) (2) (3) (4) (5) (6) . Glioma demonstrate numerous effects on the surrounding non-tumoral tissue; in particular, on the peritumoral neurons where weak expression of Bcl-2 and bax suggests that apoptosis-related proteins might be expressed in peritumoral neurons but the underlying basic mechanism that leads to seizure is not understood (6, 7) .
We investigated the possibility that neuronal damage could be actively induced by tumor cells and not only caused by constriction related to the increasing dimensions of the growing tumor.
Growth and survival of neuronal cells is highly influenced by the microenvironment being supported by the presence of neurotrophins and inhibited by factors released in the extracellular matrix by oligodendrocytes and perhaps by other surrounding cells (8) .
As oligodendrocytes are known to inhibit both axonal elongation and neuronal regeneration, we supposed that oligodendroglioma cells could also have an inhibitory effect on neurons (9) (10) (11) (12) . Oligodendrocyte inhibitory effects are generally attributed to myelin membrane components including myelin-associated glycoprotein (MAG), the Nogo proteins and oligodendrocyte-myelin glycoprotein (Omgp) (13) . The inhibitory action of all these proteins, on neurons, is reported to be mediated by interaction with the same membrane receptor: Nogo receptor (NgR), a glycosyl phosphatidyl-inositol (GPI)-anchored membrane protein (14, 15) . NgR is reported to interact with the neurotrophin receptor, p75 NTR , which mediates signal transduction (16) . NgR forms, with p75 NTR and Lingo-1, a functional complex that mediates the neurite growth inhibitory effects of its ligand by modulating the activity of Rho GTPases (17) . Recent reports, however, indicate that Nogo protein signaling can be transduced also through other pathways. In some instances, NgR signal transduction was shown to be mediated by its association with Troy, an orphan member of the TNF receptor family and, in other instances, it was reported that Nogo-66 can act on neurons by interacting with receptors different to NgR (18) (19) (20) MAG, a member of the sialic acid-dependent immunoglobulin-like lectin (SIGLEC) family, was identified as the first myelin-derived growth inhibitory protein by two distinct groups (21, 22) . It is a bifunctional protein that inhibits regrowth of adult axons, while stimulating axon growth from young neurons (23) . Moreover, dMAG, a soluble proteolytic product of MAG, which is released from isolated or damaged myelin, also potently inhibits neurite outgrowth (24) .
Nogo, identified independently by three groups, was found to have three different splice variants: Nogo A, Nogo B and Nogo C sharing a common C-terminal region which is homologous to a family of proteins called reticulons (25) (26) (27) . Nogo proteins are known to be present both in the plasma membrane and endoplasmic reticulum (28) . The Nogo A inhibitory effect on nerve outgrowth was reported to be due to the presence of two distinct domains: Nogo-66 and amino Nogo (or NiG). Nogo B and Nogo C isoforms share the Nogo-66 domain but lack amino Nogo. Nogo C is the smallest isoform and consists more or less exclusively of the Nogo-66 domain (25, 27) . Transgenic mice expressing Nogo-C in peripheral Schwann cells, show delayed peripheral nerve regeneration (29) . In Nogo B, the Nogo-66 domain is directly bound to the amino-terminal sequence of 172 amino acids also found in Nogo A (30) . The ectopic expression of Nogo B in some tumor cell lines leads to growth inhibition and apoptosis (31) .
OMgp was the latest myelin associated inhibitor of axonal growth to be identified in adult CNS (32, 33) . It is a GPIanchored protein which inhibits neurite outgrowth and proliferation of cultured neurons (34) .
All oligodendrocyte proteins identified so far for their inhibitory effect on neurons, are membrane components. The inhibitory effect of oligodendrocytes is, however, observed at several cell diameters distance and also when direct contact between oligodendrocytes and neurons is prevented (11, 35) . For these reasons, we considered the hypothesis that oligodendrocytes and oligodendroglioma cells could shed membrane vesicles and that these vesicles could exert an inhibitory effect on neurons.
Membrane vesicles originate from the plasma membrane through a mechanism morphologically similar to that of virus budding. The vesicles are relatively large and heterogeneous in size; their diameters ranging from ~100 to >1000 nm (36, 37) . Vesicle shedding is an active process that requires RNA and protein synthesis and occurs in viable cells with no signs of apoptosis or necrosis (38, 39) . Although vesicle membranes carry most of the surface antigens expressed on the cell membrane, they originate from domains of the plasma membrane selectively enriched in membrane components including HLA class I molecules, ß1 integrin and membranebound MMP-9 (40, 41) .
Vesicle shedding was generally observed in tumor cells but vesicles are also shed by several non-tumor cells (42, 43) . In normal cells, they have been reported to vehicle a variety of regulatory factors such as lectin 14, membrane-bound burstpromoting activity, human macrophage colony-stimulating factor, TGFß and interleukin-ß (44) (45) (46) (47) (48) .
Vesicle shedding was shown to be involved in cell migration and in tumor progression, a function that may be partially mediated by vesicle-bound proteinases (37, 41, (49) (50) (51) (52) . Vesicles, however, are also enriched in phosphatidyl-serine and bind annexin V; they could, therefore, exert a procoagulant effect (39, 43, 48) .
Vesicles shed by tumor cells were also shown to carry proangiogenic factors such as FGF-2, and to vehicle EMMPRIN, a transmembrane glycoprotein able to stimulate production of matrix metalloproteinases in surrounding fibroblasts (39, 53) .
Shedding of membrane-associated molecules helps tumor cells to escape from induced apoptosis. For instance, TGFß present in vesicles shed by breast carcinoma is not only a proangiogenic factor but also a very potent immunosuppressor cytokine (40) . Since antitumor lymphocytes interact with vesicles which are rich in HLA molecules and carry tumorassociated antigens, anti-tumor lymphocytes would be inhibited by shed vesicles (40, 41) .
Vesicles shed by human colorectal carcinoma cell lines were found to carry biologically active Fas antigen. Shedding of the Fas antigen is likely to decrease the susceptibility of tumor cells to Fas-L induced apoptosis: Fas-bearing vesicles are in fact capable of interacting with Fas-L efficiently, thus neutralizing its ability to induce apoptosis (54) .
On the other hand, Fas-L was present in vesicles shed by an activated human T-cell line and in vesicles shed by ovarian carcinoma and by melanoma cells; Fas-L-bearing vesicles secreted by tumor cells were capable of inducing apoptosis in Fas expressing lymphocytes (54) (55) (56) (57) .
As both in vitro and in vivo, shed vesicles appear to be important vehicles for release of signaling molecules, we analyzed the effects of vesicles shed by oligodendroglioma cells on primary cultures of rat neurons. We observed that vesicles exerted an inhibitory effect on neuronal outsprouting and caused neuronal apoptosis. We therefore looked for the presence of inhibitory and proapoptotic molecules in the vesicles. Preparation of membrane vesicles from the cell culture medium. Vesicles were prepared as previously described in sterile conditions (37) . Media conditioned by subconfluent healthy cells for 24 h were centrifuged at 2000 x g for 15 min and then at 4000 x g for 15 min. The supernatant was centrifuged at 105,000 x g for 90 min at 4˚C. Pelleted vesicles were suspended with phosphate-buffered saline pH 7.5 (PBS) and the amount of isolated vesicles was determined by measuring protein concentration by the Bradford microassay method (Bio-Rad) using bovine serum albumin (Sigma) as a standard.
Materials and methods

Animals
Treatments of neuronal cultures. Effects of vesicles and vesiclefree conditioned medium were analyzed adding them to primary cultures of neurons plated on laminin 5 h previously. Vesicles released by G26/24, NIH-3T3, and OvCa cells were tested at different concentrations (3 μg to 48 μg/ml) and their effects were analyzed after 16 or 48-72 h of culture.
Neurons were treated with phosphatidylinositol-specific phospholipase C (PI-PLC) according to Fournier et al who demonstrated that this treatment solubilized NgR from dorsal root ganglion neurons (14) . Briefly neurons were digested for 30 min with 1 U/ml of PI-PLC (Sigma); PI-PLC containing medium was removed and vesicle-free or vesicle-containing fresh medium was added.
In order to analyze the role of vesicle-associated Nogo B and Fas-L, vesicles were mixed with either 10 μg/ml of polyclonal antibodies against Nogo (Santa-Cruz), or 10 μg/ml of mouse anti Fas-L neutralizing monoclonal antibodies and incubated for 30 min at 37˚C, before adding them to neurons.
Immunofluorescence assays a) Cells cultured in monolayer.
All procedures were performed at room temperature. Cells were fixed with 2% paraformaldehyde in PBS for 15 min and then permeabilised by incubation with 0.1% Triton X-100 in PBS for an additional 15 min. After rinsing, fixed cells were saturated by incubating them for 60 min in a wet chamber with 50% FCS and 3% bovine serum albumin in PBS. The cells were then incubated for 60 min with the following primary antibodies: mouse monoclonal anti-NF, 68-kDa component, (Sigma); mouse monoclonal anti-GAP-43 (Sigma); mouse monoclonal anti-MAP-2 (Sigma); goat polyclonal anti-MAG antibodies (SantaCruz), goat polyclonal anti-Nogo antibodies (Santa-Cruz), rabbit polyclonal anti-Nogo A and B Bianca antibodies (a kind gift from Dr Schwab); rabbit polyclonal anti-Fas-L antibodies (Santa-Cruz); and mouse monoclonal anti-integrin ß1 C27 (60) .
After rinsing, cells were further incubated for 60 min with secondary antibodies and rinsed again. Immunostained samples were analyzed by confocal microscopy (Olympus 1X70 with Melles Griot laser system) or by fluorescence microscopy (Olympus BX-50 microscope equipped with a Vario Cam B/W camera).
b) Cells cultured in three-dimensional type I collagen gels.
Type I collagen (500 μl) (Rat tail BD Biosciences, sold as a 3.9 mg/ml solution in 0.02 M acetic acid) was mixed v/v with cells suspended in 10% FCS-DMEM containing 50 mM NaHCO 3 at a concentration of ~300,000 cells/ml, and plated, 100 μl per well, in 96-multiwell plates (Costar 3596). As soon as gels had polymerised, 200 μl of complete medium were added to each well. After 6 days of incubation, cells were fixed by addition of 3.7% formaldehyde (Carlo Erba) in PBS. After rinsing, fixed cells were incubated for 2 h at room temperature with 1 μg/ml phalloidin FITC-labelled (Sigma).
Vitality assay. Cell apoptosis was observed by staining the cells with a combination of the fluorescent DNA-binding dyes, acridine orange (AO) and ethidium bromide (EB), 100 μg/ml in PBS for each dye (AO/EB colorimetric assay). The differential uptake of these two dyes allowed the identification of viable and non-viable cells by fluorescence microscopy. Normal nuclei in live cells appeared bright green; apoptotic nuclei in dead cells appeared bright orange with highly condensed chromatin.
Western blot analyses. Total proteins were separated by SDS-PAGE and blotted onto a nitrocellulose membrane (Hybond; Amersham Biosciences) previously saturated with 3% fat-free milk in TBS-T for 3 h. After incubation, membranes were treated overnight with the following antibodies: mouse monoclonal anti-NF (Sigma); mouse monoclonal anti-GAP-43 (Sigma); mouse monoclonal anti-MAP-2 (Sigma); rabbit polyclonal anti-caspase-3 (Santa-Cruz); rabbit polyclonal anti-procaspase-8 (Santa-Cruz); rabbit polyclonal anti-Bcl-2 (Santa-Cruz); rabbit polyclonal anti-Fas-L (Santa-Cruz); rabbit polyclonal anti-Nogo A and B Bianca and mouse monoclonal 11C7 anti-Nogo A (kind gifts from Dr Schwab). Membranes were extensively rinsed with TBS-T and incubated for 2 h with secondary antibodies. Immunocomplexes were visualized with the ECL Western blot kit (Amersham Biosciences) using Hyperfilms. Fig. 1 , G26/24 cells release in their culture media vesicular structures which can be observed by phase contrast microscopy (Fig. 1a) . Shed vesicles can also be easily observed when cells are cultured in three-dimensional collagen gels in which they remain trapped (Fig. 1b and c) . Vesicles shed by G26/24 cells are much larger than exosomes (the diameter of which ranges from 10 to 90 nm) and are similar to or even larger than extracellular vesicles shed by several other tumor cell lines (39, 41) . Diameters of vesicles shed by G26/24 oligodendroglioma cells (Fig. 1c) and by NIH-3T3 cells (Fig. 1d) are similar.
Results
G26/24 oligodendroglioma cells release membrane vesicles similar to those shed by NIH-3T3 cells. As shown in
Vesicles were recovered from conditioned media as previously described (37) . We obtained ~80 μg of vesicle proteins from complete media in which ~20 million subconfluent cells had been cultured for 24 h. As described for other cell lines, FCS stimulated vesicle shedding. However, while 8701 BC and MCF-7 breast carcinoma and Sk-Hep-1 hepatocarcinoma cells cultured in serum free media do not release a measurable amount of vesicles, G26/24 oligodendroglioma cells, as well as NIH-3T3 cells, release a decreased but still measurable amount of vesicles (30 μg instead of 80 μg) also when in serum-free media.
Effects of G26/24 shed vesicles on primary fetal rat cortical neurons. Effects of vesicles shed by G26/24 cells were tested by adding them to primary cultures of neurons. Neurons were prepared from fetal rat cortices at the 16th gestational day and cultured on laminin as described by Cestelli et al (58) . Vesicles were added to primary cultures of neurons when they had already started to produce neurites (5 h after they had been plated in multiwell dishes at ~5x10 5 /cm 2 ). Approximately 16 h later, an inhibitory effect of vesicles on neurite sprouting was already visible ( Fig. 2A and C) . After longer periods, (48-72 h) most neurons underwent apoptosis. (Fig. 2B  and D) . As shown in the figure, the effect was dose-dependent and already visible at a vesicle concentration of 3 μg/ml, (i.e. the concentration of vesicles in one ml of G26/24 conditioned medium). In a different set of experiments, vesicles were added five days after neurons had been plated, the effects on neurite extention and cell vitality were very similar to those shown in Fig. 2 . When neurons were treated with vesicle-free G26/24 oligodendroglioma conditioned media or with different concentrations of vesicles shed by NIH-3T3 cells, neither morphological nor proapoptotic effects were observed ( Fig. 2A and B, lane 7 and data not shown). When vesicles shed by G26/24 cells were tested on primary cultures of astrocytes, the cell morphology and vitality of these cells were not affected (data not shown). Fig. 3A , Western analyses demonstrated that, after 16-h treatment with vesicles, the expression of NF p68, MAP-2 and GAP 43 was decreased; less significant differences were also observed for total actin and tubulin expression and, therefore, we standardized the Western analyses with respect to Coomassie-blue staining. Immunofluorescence analyses showed that number and extention of neurites were significantly reduced in vesicletreated cells. Distribution of neurite-associated proteins was consequently modified, with GAP-43 and MAP-2 clearly localized in the cytoplasm (Fig. 3B) . Fig. 3C shows that, after 48-72 h, induction of neuronal apoptosis was associated with a decrease in the expression level of procaspase-3 and -8 and with an increase in the active form of caspase-3. The anti-procaspase-8 polyclonal antibody we utilized for these experiments (Santa-Cruz sc-7890) does not react with the active form of caspase-8; we were therefore unable to show the increase in active caspase-8 which is, however, suggested by the disappearance of the proenzymatic form of this enzyme. A decrease in Bcl-2 expression level was also evident. At the same time, expression of MAP-2, only slightly decreased after 16 h of treatment, was clearly affected.
Modifications of neuronal protein expression induced by vesicle treatments. As shown in
Expression of myelin components by G26/24 cells and shed vesicles.
In an attempt to identify vesicle components responsible for the observed inhibitory and proapoptotic effects on neurons, G26/24 cells and their shed vesicles were tested for expression of myelin membrane components known for having inhibitory effects on neurons. Cells were found to be negative for MAG (Fig. 4Aa ) but positive for Nogo (Fig. 4Ab) . Nogo was observed to localize preferentially in specific regions of the cell plasma membrane which appear to correspond to sites of vesicle budding (Fig. 4Ac) ; they were in fact also specifically marked by anti-ß1 integrin antibodies (Fig. 4Ad) , previously reported to be clustered in shed vesicles (38) . In addition antibodies clearly labeled isolated vesicles placed on a poly-L-lysine-coated glass cover (Fig. 4Ae) .
In order to identify the Nogo isoform(s) expressed in G26/24 shed vesicles, we performed Western analyses utilizing Bianca and 11C7 antibodies, a kind gift from Dr Schwab. Bianca, rabbit polyclonal antibodies recognize the protein N-terminal domain which is expressed both in Nogo A and Nogo B isoforms, 11C7 is a monoclonal antibody recognizing a specific region present exclusively in the Nogo A isoform (30) . As shown in Fig. 4B , Western analyses demonstrated that the Nogo isoform present in vesicles shed by G26/24 cells is Nogo B while Nogo A is absent. As positive control, in these Western analyses, we utilized an extract of rat neurons. The slight difference in electrophoretic migration of the components marked by Bianca antibodies in neurons (from rat) and shed vesicles (from mouse oligodendroglioma cells) is probably due to the known difference in the molecular mass of Nogo B proteins in rat (55 kDa) and mouse (40-50 kDa) (30, 61) .
To evaluate the role of Nogo B in the inhibitory effects of vesicles shed by G26/24 oligodendroglioma cells, before adding vesicles, neurons were treated with PI-PLC in order to solubilize the Nogo receptor (NgR). The treatment did not affect neuronal morphology and vitality (data not shown) but the inhibitory effect of vesicles was unchanged (Fig. 4C) . In a different set of experiments, anti-Nogo polyclonal antibodies (Santa-Cruz sc-11027) were added to neurons together with shed vesicles. At the maximal tested concentration (20 μg/ml), antibodies were unable to counteract the inhibitory effects of vesicles (data not shown).
Vesicles shed by G26/24 cells express Fas-ligand.
Vesicles shed by some tumor cells are known to carry Fas-L in a biologically active form (54) (55) (56) (57) . We therefore analyzed G26/24 cells and vesicles for the presence of this molecule: both cells and vesicles were clearly positive (Fig. 5A and B) . Moreover, since vesicles shed by ovarian carcinoma cells had been reported to express Fas-L, we also tested, as a reference, vesicles shed by OvCa, a stabilized human ovarian carcinoma cell line. Vesicles shed by G26/24 oligodendroglioma cells appear to express Fas-L at an even higher level compared to vesicles shed by OvCa ovarian carcinoma cells (Fig. 5B) .
Functional role of Fas-L in vesicles shed by G26/24 oligodendroglioma cells.
To evaluate the role of Fas-L in the inhibitory and proapoptotic effects vesicles shed by G26/24 oligodendroglioma cells, before adding them to neurons, vesicles were treated with functional anti-Fas-L antibodies. In order to optimize their effects, antibodies (10 μg/ml) were added again to the cells after 24 h of culture. As shown in Fig. 5C and D, antibodies largely counteracted both the inhibitory effect of vesicles on neurite outgrowth (Fig. 5C ) and their proapoptotic effects (5D).
Since Fas-L is expressed both in vesicles shed by G26/24 and by OvCa cells, to analyze the role of vesicle-associated Fas-L in the inhibitory effects of vesicles on neurons, we also tested vesicles shed by OvCa cells on neuronal primary cultures. The results shown in Fig. 5C indicate that vesicles shed by these ovarian carcinoma cells are as active in inhibiting neurite sprouting and in inducing neuronal apoptosis as vesicles shed by G26/24 cells. Anti-Fas-L antibodies counteracted the effects of OvCa vesicles at levels comparable to those observed with G26/24 vesicles. Therefore, the incomplete reversion is probably due to the large amount of Fas-L expressed in vesicles shed by both cell lines. We therefore conclude that the effects of G26/24 vesicles on primary neuronal cultures are largely or exclusively due to Fas-L expression.
Discussion
Although they are slowly growing tumors, oligodendrogliomas are a frequent cause of death because they cause extensive neuronal damage. We aimed to analyze the possibility that oligodendrogliomas can induce neuronal loss by production of active molecules. We also hypothesized that the inhibitory mechanism could be mediated by shed membrane vesicles, structures which are involved in several mechanisms of cellcell and cell-matrix interactions (62) .
Both hypotheses were clearly confirmed by our results. We report that oligodendroglioma cells shed membrane vesicles, and that these vesicles inhibit neurite sprouting and cause neuronal apoptosis. The inhibitory effect was not observed when vesicles shed by NIH-3T3 cells were tested.
Proapoptotic effects of vesicles were dose-dependent and observable even when 3 μg of vesicles, i.e. the amount of vesicles recovered from one ml of G26/24 conditioned medium, was added to one ml of neuronal cultures. The proapoptotic effect is therefore induced also when concentrations of tumorderived vesicles are similar to those one could imagine to occur in vivo when an oligodendroglioma tumor is growing inside the central nervous system (CNS). When vesicle-free G26/24 conditioned medium was added to neurons, no inhibitory or proapoptotic effects were observed; active molecules are, therefore, associated with shed vesicles.
In an attempt to identify the vesicle-associated molecules responsible for inhibitory and proapoptotic effects on neurons, we tested G26/24 shed vesicles for the presence of myelin components with well-known negative effects on neurons. Among these molecules, MAG and Nogo A proteins were not detected. On the contrary, Nogo B was present in shed vesicles. This protein could have inhibitory effects on neurons because it includes the Nogo-66 domain which is known to interact with NgR. In order to evaluate the role of Nogo B, we tried to neutralize Nogo signaling by removing the NgR from neurons by PI-PLC digestion. The treatment was without effect.
However, Western analyses indicated that, in fetal cortical neurons, NgR expression is extremely low, at limit of detection by standard Western blot procedures, a result which is in agreement with data reported by Mingorance et al who detected NgR in hippocampal neurons only in the postnatal stage (63) .
Interestingly, recent reports indicate that Nogo-66 can act on neurons also by interacting with receptors different to NgR; postnatal dorsal root ganglion or cerebellar granule neurons from mice knock-out for NgR were indeed still inhibited by Nogo-66 (20) .
The inhibitory effects of vesicles on neurite outgrowth could, therefore, be due to Nogo B interaction with a not yet identified receptor, different from NgR. Nevertheless, our observation that addition of anti-Nogo polyclonal antibodies does not prevent the inhibitory effect of vesicles seems to exclude Nogo B involvement in the process.
Although Nogo proteins were never reported to induce neuronal apoptosis, Nogo B is known for having proapoptotic effects in some tumor cells in which it is overexpressed (31) . The inhibitory effects of Nogo proteins on neurite sprouting are considered to be due to the interactions of the plasma membrane associated Nogo proteins with the Nogo receptor, the proapoptotic effects of Nogo B in cells in which the protein is overexpressed are, however, suggested to be due to the interaction of the ER-associated molecule with cytoplasmic antiapoptotic proteins such as Bcl-2 and Bcl-X L , causing their sequestration (64) . More recently, Qi et al reported that Nogo B associates with a protein of the endoplasmic reticulum (ASYIP), and that this association is probably involved in its proapoptotic effects (65) .
The paracrin proapoptotic effects of G26/24 vesicles on neurons could be mediated by Nogo B induced sequestration of antiapoptotic molecules, only if the molecule were internalized by fusion of shed vesicles with the plasma membrane of the target cells. As insertion of membrane components of vesicles shed by one kind of cells into the cell membrane of a target cell has been reported, this possibility cannot be ruled out (66) . Non-tumor cells were, however, reported to be less sensitive to Nogo B proapoptotic activity when compared with tumor cells (31) . Moreover, the induction of apoptosis of neuronal cells by shed vesicles is associated with caspase-8 activation, and this result points to a pro-apoptotic mechanism based on the activation of cell surface receptors. We therefore conclude that Nogo B does not play a prominent role in the proapoptotic effects caused on neurons by G26/24 shed vesicles.
Since inhibitory myelin components were not proved to be responsible for the vesicle effects, we tested vesicles shed by oligodendroglioma cells for the presence of Fas-L. This latter molecule had been identified in vesicles shed by other kinds of tumor cells. It was also reported that vesicle-bound Fas-L is far more active than soluble Fas-L, and that it induces apoptosis of activated T lymphocytes (56) . Our analyses demonstrated that Fas-L is indeed present in vesicles shed by G26/24 oligodendroglioma cells; moreover, functional monoclonal antibodies against Fas-L are able to partially revert the inhibitory effects of vesicles on neurite growth and to counteract their proapoptotic effects on neurons. Fas receptor is reported to be expressed both in neurons and astrocytes (67) . The observation that vesicles shed by G26/24 oligodendroglioma cells do not affect astrocyte vitality agrees, however, with data showing that, in astrocytes, Fas/Fas-L interaction is not associated with astrocyte apoptosis but instead causes a response involving production of proangiogenic molecules (68) (69) (70) . NIH-3T3 cells do not express a significant amount of Fas-L (data not shown) and, accordingly, NIH-3T3 do not induce neuronal apoptosis (71) . Vesicles shed by ovarian carcinoma cells, which carry Fas-L, have a proapoptotic effect on neurons comparable to that of vesicles shed by oligodendroglioma cells. Also in this case, anti-Fas-L antibodies caused partial reversion of inhibitory and proapoptotic effects on neurons.
Fas-L appears, therefore, as one of the signaling molecules involved in the inhibitory and proapoptotic effects that vesicles shed by oligodendroglioma cells exert on neurons. Fas-L is known to play important roles in the brain and Fas-L expression in microglia is upregulated in vitro in hypoxiaischemia. In the ischemic penumbra, many cells die by apoptosis and it was found that neuronal apoptosis could be significantly reduced by Fas-L antibodies (72) . However, Desbarats et al (73) and, recently, Zuliani et al (74) reported that Fas-FasL interaction does not induce apoptosis but, on the contrary, induces an increase of neuronal branching in mouse developing brain. These results are in contrast with ours. Discrepancies probably depend on differences in experimental conditions; we utilized a tumor system and, moreover, FasL associated with tumor vesicles was reported to be especially active.
The presence of Fas-L in vesicles shed by tumor cells is generally considered as part of the mechanism by which tumors acquire the capability to escape from host immune surveillance. The presence of the molecule in vesicles shed by oligodendrogliomas appears to have an additional meaning in allowing production of a cell-free environment in which tumor cells can grow. The brain is an immune-privileged organ in which immune response is decreased by the absence of lymphatic vases and by the presence of the blood-brain barrier; it is, however, a narrow place, delimited by bones and other barriers, in which tumors would be unable to grow unless the space in which cells are growing is obtained by killing surrounding cells.
The present results indicate once more that shed vesicles play a very important role in cell-cell interactions and that they are specifically involved in several tumor progression mechanisms.
